{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 3.0', 'CONFIDENTIAL', 'BCX7353-302', 'Lumry, W. R., A. J. Castaldo, M. K. Vernon, M. B. Blaustein, D. A. Wilson and P. T. Horn', '(2010). \"The humanistic burden of hereditary angioedema: Impact on health-related quality of', 'life, productivity, and depression.\" Allergy Asthma Proc 31(5): 407-414.', 'Riedl, M., A. Banerji and R. Gower (2013). \"Current Medical Management of Hereditary', \"Angioedema (HAE): Follow-up to a Large Survey of US Physicians.' AAAI Annual Meeting,\", 'San Diego, CA.', 'Saxena, P., P. Thompson, Y. d\\'Udekem and I. E. Konstantinov (2011). \"Kallikrein-kinin system:', \"a surgical perspective in post-aprotinin era.' J Surg Res 167(1): 70-77.\", 'Shire (2018). \"Takhyzyro (lanadelumab-flyo) injection, for subcutaneous use US Prescribing', 'Information.\" 9.', 'Shire ViroPharma Inc. (2018). \"CINRYZE (C1 Esterase Inhibitor [Human]) US Prescribing', 'Information \": 9.', 'Weller, K., M. Magerl, A. Peveling-Oberhag, P. Martus, P. Staubach and M. Maurer (2016).', '\"The Angioedema Quality of Life Questionnaire (AE-QoL) - assessment of sensitivity to change', 'and minimal clinically important difference.\" Allergy 71(8): 1203-1209.', 'Zuraw, B. L., A. Banerji, J. A. Bernstein, P. J. Busse, S. C. Christiansen, M. Davis-Lorton, M.', 'M. Frank, H. H. Li, W. R. Lumry and M. Riedl (2013). \"US Hereditary Angioedema Association', 'Medical Advisory Board 2013 Recommendations for the Management of Hereditary', 'Angioedema Due to C1 Inhibitor Deficiency.\" J Allergy Clin Immunol Pract 1(5): 458-467.', 'Zuraw, B. L. and S. C. Christiansen (2011). \"Pathophysiology of hereditary angioedema.\\' Am J', 'Rhinol Allergy 25(6): 373-378.', '104']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 3.0', 'CONFIDENTIAL', 'BCX7353-302', '16.', 'APPENDICES', '16.1.', 'DMID Adult Toxicity Table (DRAFT, Publish Date: November 2007)', 'Copies of the DMID Toxicity Table will be available to the medical staff throughout the project.', '105']['DIVISION OF MICROBIOLOGY AND INFECTIOUS', 'DISEASES (DMID) ADULT TOXICITY TABLE', 'NOVEMBER 2007', 'DRAFT', 'ABBREVIATIONS: Abbreviations utilized in the Table:', 'ULN = Upper Limit of Normal', 'LLN = Lower Limit of Normal', 'Rx = Therapy', 'Req = Required', 'Mod = Moderate', 'IV = Intravenous', 'ADL = Activities of Daily Living', 'Dec = Decreased', 'ESTIMATING SEVERITY GRADE', 'For abnormalities NOT found elsewhere in the Toxicity Tables use the scale below to', 'estimate grade of severity:', 'GRADE 1', 'Mild', 'Transient or mild discomfort', '(<48 hours); no medical intervention/therapy required', 'GRADE 2', 'Moderate', 'Mild to moderate limitation in', 'activity - some assistance may be needed; no or minimal', 'medical intervention/therapy required', 'GRADE 3', 'Severe', 'Marked limitation in activity, some', 'assistance usually required; medical intervention/therapy', 'required, hospitalizations possible', 'GRADE 4', 'Life-threatening', 'Extreme limitation in activity,', 'significant assistance required; significant medical', 'intervention/therapy required, hospitalization or hospice', 'care probable', 'SERIOUS OR LIFE-THREATENING AEs', 'ANY clinical event deemed by the clinician to be serious or life-threatening should be', 'considered a grade 4 event. Clinical events considered to be serious or life-threatening', 'include, but are not limited to: seizures, coma, tetany, diabetic ketoacidosis,', 'disseminated intravascular coagulation, diffuse petechiae, paralysis, acute psychosis,', 'severe depression.', 'COMMENTS REGARDING THE USE OF THESE TABLES', \"Standardized and commonly used toxicity tables (Division of AIDS, NCI's\", 'Common Toxicity Criteria (CTC), and World Health Organization (WHO)) have', 'been adapted for use by the Division of Microbiology and Infectious Diseases', '(DMID) and modified to better meet the needs of participants in DMID trials.', 'For parameters not included in the following Toxicity Tables, sites should refer to', 'the \"Guide For Estimating Severity Grade\\' located above.', 'Criteria are generally grouped by body system.', 'Some protocols may have additional protocol specific grading criteria, which will', 'supercede the use of these tables for specified criteria.']\n\n###\n\n", "completion": "END"}